Figure 4
Figure 4. IRF-1 ChIP assay. Day 6 MDDCs were treated with HIV-1BaL or IFNγ for 48 hours. A ChIP assay was then performed with an IRF-1 antibody, and qPCR primers were directed toward IRF-2 or IFIT5 promoter sequences to determine IRF-1 binding. (Lane 1) HIV-1–treated MDDCs no IRF-1 antibody, (lane 2) HIV-1–treated MDDCs plus IRF-1 antibody, (lane 3) IFNγ-treated MDDCs no IRF-1 antibody, (lane 4) IFNγ-treated MDDCs plus IRF-1 antibody, (lane 5) cell input DNA, (lane 6) PCR negative no DNA control, and (lane 7) ChIP reagents only negative control.

IRF-1 ChIP assay. Day 6 MDDCs were treated with HIV-1BaL or IFNγ for 48 hours. A ChIP assay was then performed with an IRF-1 antibody, and qPCR primers were directed toward IRF-2 or IFIT5 promoter sequences to determine IRF-1 binding. (Lane 1) HIV-1–treated MDDCs no IRF-1 antibody, (lane 2) HIV-1–treated MDDCs plus IRF-1 antibody, (lane 3) IFNγ-treated MDDCs no IRF-1 antibody, (lane 4) IFNγ-treated MDDCs plus IRF-1 antibody, (lane 5) cell input DNA, (lane 6) PCR negative no DNA control, and (lane 7) ChIP reagents only negative control.

Close Modal

or Create an Account

Close Modal
Close Modal